AstraZeneca considers moving stock market listing to US, impacting London market

From Yahoo Finance: 2025-07-01 12:13:00

AstraZeneca’s CEO, Sir Pascal Soriot, is considering moving the company’s stock market listing to the US, indicating investor support and potential benefits in financing and shareholder base expansion.

The potential move would deal a significant blow to London’s stock exchange and the UK government, while aligning with Donald Trump’s push for increased US investments in drug companies.

AstraZeneca’s frustration with the UK government’s tax policies and healthcare system support the potential move to the US, threatening the UK’s life sciences sector plan.

Speculation of AstraZeneca’s departure has been ongoing, with the company already trading American depositary receipts in the US, requiring board approval for any listing switch.

The UK government aims to drive economic growth through the life sciences sector, but AstraZeneca’s potential departure could setback progress and play into the Trump narrative of attracting pharma companies to the US.



Read more at Yahoo Finance: AstraZeneca may quit London stock market